Theralase Validates Herpes Treatment with Ruvidar

Theralase Technologies has confirmed its previous University of Manitoba research, showcasing the safety and efficacy of Ruvidar in treating the Herpes Simplex Virus Type 1 (HSV-1) in animal models. This Toronto-based pharmaceutical company focuses on creating drug-activated compounds for combatting cancers, bacteria, and viruses.

In their latest study, mice infected with HSV-1 received topical applications of a 1% Ruvidar solution, leading to complete healing of lesions after four days. This development supports Ruvidar's potential for effectively treating HSV-1 cutaneous lesions.

The global HSV treatment market, valued at $2.5 billion in 2023, is projected to grow due to rising concerns about HSV infections, which remain highly contagious. Theralase's findings provide a foundation for future clinical programs targeting HSV treatment.